Spotlight Growth
No Result
View All Result
Friday, March 31, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company

by admin
March 6, 2023
in Bio/Med/Pharma
0
TCR2 Therapeutics NASDAQ TCRR Adaptimmune NASDAQ ADAP Merger Spotlight Growth

TCR2 Therapeutics NASDAQ TCRR Adaptimmune NASDAQ ADAP Merger Spotlight Growth

TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of novel T-cell receptor therapies for patients undergoing care for cancer. Shares of the immunotherapeutic company are rallying 31% through early trading on Monday, March 6, 2023. Over the past three months, TCR2 Therapeutics has seen average daily volume of 270,400 shares. However, volume of 12.26 million shares or dollar volume of around $19.37 million, has already exchanged hands through early trading.

Shares of TCR2 Therapeutics are gaining after the company announced that it has entered into a definitive agreement to merge with Adaptimmune Therapeutics plc (NASDAQ: ADAP) in an all-stock transaction for an undisclosed total transaction value. Under the terms of the merger, TCR2 Therapeutics shareholders will receive 1.5117 Adaptimmune ADS for each TCRR share. As a result, Adaptimmune shareholders will own ~75% of the combined company and TCR2 Therapeutics shareholders will own ~25% of the combined company post-merger.

Both companies see substantial benefits across clinical development and product delivery from its proposed strategic combination. As a result of the perceived synergies and complementary technological platforms, the combined company’s cash runway is estimated to extend in 2026, once the transaction is closed.

The combined company would become an instant major new player in the cell therapy space, specifically for treating solid tumors. This represents a massive market opportunity that still has not seen a strong involvement from a cell therapy basis.

In addition, the combined company will hold two clinically-validated and complementary technology platforms in SPEAR and TRuC T-cells. This will allow for the enablement of both intracellular targets and extracellular targets, which broadens the number of addressable cancers that can be potentially targeted.

Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics: “The strategic rationale for this combination and the operating benefits are highly compelling for both Adaptimmune and TCR² shareholders. The combination of our two companies not only sets the stage for near-term execution but also positions the new company for the longer-term. We jointly have an array of next-generation innovations that we will integrate to address the tumor micro-environment using both autologous and allogeneic approaches. Focus and specialization are critical in the cell therapy space and we believe the combined company has the technologies necessary to succeed. I am delighted that this combination provides a strong foundation to commercialize curative therapies for people with cancer.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: acquisitionADAPADAP stockAdaptimmune Therapeuticsbiopharmabiopharmaceuticalsbiotechbiotechnologycancer treatmentcommon stockday tradingemerging growthinvestinginvesting newsinvestmentmedicalMergermerger newsmicrocap stocksNASDAQnewsoncologypharmaceuticalspublic companyservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstock newsstocksTCR2 TherapeuticsTCRRTCRR stocktop stockstradingtreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Asure Software NASDAQ ASUR Partner Harbor Compliance Spotlight Growth

Asure Software (NASDAQ: ASUR) Partners with Harbor Compliance to Help SMBs Streamline Registration Compliance

March 30, 2023
EVgo NASDAQ EVGO FY 2022 and Q4 2022 Financial Results Spotlight Growth

EVgo (NASDAQ: EVGO) Shares Q4 and FY 2022 Financial Results Showing Massive Revenue Growth, Issues Guidance For 2023

March 30, 2023
SCYNEXIS Nasdaq SCYX GSK NYSE GSK Exclusive Agreement Fungal Infection Spotlight Growth

SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections

March 30, 2023
Four Pillars of Financial Risk Management Spotlight Growth

The Four Pillars of Financial Risk Management

March 29, 2023

Recent News

Asure Software NASDAQ ASUR Partner Harbor Compliance Spotlight Growth

Asure Software (NASDAQ: ASUR) Partners with Harbor Compliance to Help SMBs Streamline Registration Compliance

March 30, 2023
EVgo NASDAQ EVGO FY 2022 and Q4 2022 Financial Results Spotlight Growth

EVgo (NASDAQ: EVGO) Shares Q4 and FY 2022 Financial Results Showing Massive Revenue Growth, Issues Guidance For 2023

March 30, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested